MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT04739800 | ACTIVE_NOT_RECRUITING | PHASE2
120 participants

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-06-10
Completion:
2023-01-26
Conditions
  • Fallopian Tube Mucinous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Platinum-Refractory Fallopian Tube Carcinoma
  • Platinum-Refractory Ovarian Carcinoma
  • Platinum-Refractory Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Mucinous Adenocarcinoma
  • Recurrent Fallopian Tube Transitional Cell Carcinoma
  • Recurrent Fallopian Tube Undifferentiated Carcinoma
  • Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Ovarian Mucinous Adenocarcinoma
  • Recurrent Ovarian Seromucinous Carcinoma
  • Recurrent Ovarian Transitional Cell Carcinoma
  • Recurrent Ovarian Undifferentiated Carcinoma
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Transitional Cell Carcinoma
  • Recurrent Primary Peritoneal Undifferentiated Carcinoma
  • Refractory Fallopian Tube Clear Cell Adenocarcinoma
  • Refractory Fallopian Tube Endometrioid Adenocarcinoma
  • Refractory Fallopian Tube High Grade Serous Adenocarcinoma
  • Refractory Fallopian Tube Mucinous Adenocarcinoma
  • Refractory Fallopian Tube Transitional Cell Carcinoma
  • Refractory Fallopian Tube Undifferentiated Carcinoma
  • Refractory Low Grade Fallopian Tube Serous Adenocarcinoma
  • Refractory Ovarian Clear Cell Adenocarcinoma
  • Refractory Ovarian Endometrioid Adenocarcinoma
  • Refractory Ovarian High Grade Serous Adenocarcinoma
  • Refractory Ovarian Low Grade Serous Adenocarcinoma
  • Refractory Ovarian Mucinous Adenocarcinoma
  • Refractory Ovarian Seromucinous Carcinoma
  • Refractory Ovarian Transitional Cell Carcinoma
  • Refractory Ovarian Undifferentiated Carcinoma
  • Refractory Primary Peritoneal Clear Cell Adenocarcinoma
  • Refractory Primary Peritoneal Endometrioid Adenocarcinoma
  • Refractory Primary Peritoneal High Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Transitional Cell Carcinoma
  • Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT04708418 | ACTIVE_NOT_RECRUITING | PHASE2
60 participants

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-10-15
Completion:
2026-12-31
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Melanoma of Unknown Primary
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Recurrent Cutaneous Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT04676529 | COMPLETED | PHASE1/PHASE2
43 participants

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-02-18
Completion:
2025-07-09
Conditions
  • Myelofibrosis
  • Primary Myelofibrosis (PMF)
  • Post- Essential Thrombocythemia Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis
Interventions
  • DRUG
Results Available
NCT04579224 | ACTIVE_NOT_RECRUITING | PHASE3
184 participants

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-06-28
Completion:
2030-08-15
Conditions
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Refractory Bladder Urothelial Carcinoma
  • Refractory Urothelial Carcinoma
  • Stage IV Bladder Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03984448 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
363 participants

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2019-10-22
Completion:
2028-04-01
Conditions
  • Diffuse Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Double-Expressor Lymphoma
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03907488 | ACTIVE_NOT_RECRUITING | PHASE3
994 participants

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2019-08-29
Completion:
2024-03-31
Conditions
  • Ann Arbor Stage III Hodgkin Lymphoma
  • Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
  • Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
  • Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
  • Ann Arbor Stage IV Hodgkin Lymphoma
  • Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
  • Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
  • Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
  • Classic Hodgkin Lymphoma
  • Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
  • OTHER
  • RADIATION
Results Available
NCT03811015 | ACTIVE_NOT_RECRUITING | PHASE3
636 participants

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2019-08-16
Completion:
2027-01-01
Conditions
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
  • RADIATION
  • BIOLOGICAL
No Results Yet
NCT03712605 | ACTIVE_NOT_RECRUITING | PHASE3
280 participants

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2018-11-15
Completion:
2026-12-31
Conditions
  • Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
  • OTHER
  • PROCEDURE
  • BIOLOGICAL
  • RADIATION
No Results Yet
NCT03698019 | ACTIVE_NOT_RECRUITING | PHASE2
313 participants

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2019-02-15
Completion:
2022-09-01
Conditions
  • Acral Lentiginous Melanoma
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Mucosal Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
Results Available
NCT03375320 | ACTIVE_NOT_RECRUITING | PHASE3
298 participants

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2018-10-26
Completion:
2023-08-23
Conditions
  • Functioning Pancreatic Neuroendocrine Tumor
  • Intermediate Grade Lung Neuroendocrine Neoplasm
  • Locally Advanced Digestive System Neuroendocrine Neoplasm
  • Locally Advanced Digestive System Neuroendocrine Tumor G1
  • Locally Advanced Lung Neuroendocrine Neoplasm
  • Locally Advanced Pancreatic Neuroendocrine Tumor
  • Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
  • Low Grade Lung Neuroendocrine Neoplasm
  • Lung Neuroendocrine Tumor
  • Lung Neuroendocrine Tumor G2
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Metastatic Digestive System Neuroendocrine Tumor G1
  • Metastatic Lung Neuroendocrine Neoplasm
  • Metastatic Lung Neuroendocrine Tumor
  • Metastatic Pancreatic Neuroendocrine Neoplasm
  • Metastatic Pancreatic Neuroendocrine Tumor
  • Metastatic Thymus Neuroendocrine Neoplasm
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumor
  • Neuroendocrine Tumor G2
  • Non-Functioning Pancreatic Neuroendocrine Tumor
  • Pancreatic Serotonin-Producing Neuroendocrine Tumor
  • Thymus Neuroendocrine Tumor
  • Unresectable Digestive System Neuroendocrine Neoplasm
  • Unresectable Digestive System Neuroendocrine Tumor G1
  • Unresectable Lung Neuroendocrine Neoplasm
  • Unresectable Pancreatic Neuroendocrine Neoplasm
  • Unresectable Thymus Neuroendocrine Neoplasm
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page